Artiva Biotherapeutics Inc.

Animal Exploitation (Testing): Yes Link: https://investors.artivabio.com/News-and-Events/news/news-details/2022/Artiva-Biotherapeutics-Presents-Preclinical-Data-for-AB-101-an-Optimized-Allogeneic-NK-Cell-Therapy-Candidate-at-SITC-2022-Annual-Meeting/default.aspx Short Description: The company is in the business of developing new drugs (cell therapies) for cancer and autoimmune diseases. This field is subject to mandatory regulatory requirements for preclinical studies and toxicology testing that require the use of animals for safety and efficacy evaluations. Exact Quote from Link: “Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting.” (The term “Preclinical Data” for a drug candidate confirms the required animal testing stage of development.)